A detailed history of Israel Englander (Millennium Management LLC) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 11,794 shares of TGTX stock, worth $413,615. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,794
Previous 1,457,908 99.19%
Holding current value
$413,615
Previous $25.9 Million 98.94%
% of portfolio
0.0%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$17.21 - $25.28 $24.9 Million - $36.6 Million
-1,446,114 Reduced 99.19%
11,794 $275,000
Q2 2024

Aug 14, 2024

SELL
$13.32 - $19.19 $27 Million - $38.9 Million
-2,026,138 Reduced 58.15%
1,457,908 $25.9 Million
Q1 2024

May 15, 2024

BUY
$13.02 - $21.3 $7.23 Million - $11.8 Million
555,258 Added 18.96%
3,484,046 $53 Million
Q4 2023

Feb 14, 2024

BUY
$6.68 - $18.81 $14 Million - $39.4 Million
2,093,658 Added 250.7%
2,928,788 $50 Million
Q2 2023

Aug 14, 2023

SELL
$15.48 - $35.0 $27.7 Million - $62.7 Million
-1,791,443 Reduced 68.2%
835,130 $20.7 Million
Q1 2023

May 15, 2023

SELL
$10.23 - $19.34 $36.5 Million - $69 Million
-3,566,599 Reduced 57.59%
2,626,573 $39.5 Million
Q4 2022

Feb 14, 2023

BUY
$5.01 - $11.83 $11.2 Million - $26.4 Million
2,230,975 Added 56.31%
6,193,172 $73.3 Million
Q3 2022

Nov 14, 2022

SELL
$4.57 - $8.4 $4.55 Million - $8.37 Million
-996,355 Reduced 20.09%
3,962,197 $23.5 Million
Q2 2022

Aug 15, 2022

BUY
$3.74 - $10.66 $10.4 Million - $29.7 Million
2,781,903 Added 127.81%
4,958,552 $21.1 Million
Q1 2022

May 16, 2022

BUY
$7.81 - $20.45 $12.8 Million - $33.5 Million
1,640,258 Added 305.8%
2,176,649 $20.7 Million
Q4 2021

Feb 14, 2022

BUY
$15.2 - $35.51 $7.88 Million - $18.4 Million
518,633 Added 2920.56%
536,391 $10.2 Million
Q3 2021

Nov 15, 2021

SELL
$21.78 - $40.45 $2.21 Million - $4.1 Million
-101,456 Reduced 85.1%
17,758 $591,000
Q2 2021

Aug 16, 2021

SELL
$32.5 - $48.96 $6.41 Million - $9.66 Million
-197,257 Reduced 62.33%
119,214 $4.62 Million
Q1 2021

May 17, 2021

SELL
$41.61 - $54.3 $9.49 Million - $12.4 Million
-228,105 Reduced 41.89%
316,471 $15.3 Million
Q4 2020

Feb 16, 2021

SELL
$25.27 - $54.9 $1.33 Million - $2.9 Million
-52,814 Reduced 8.84%
544,576 $28.3 Million
Q3 2020

Nov 16, 2020

SELL
$18.49 - $27.24 $14.6 Million - $21.5 Million
-789,069 Reduced 56.91%
597,390 $16 Million
Q2 2020

Aug 14, 2020

BUY
$8.9 - $21.84 $2.69 Million - $6.59 Million
301,818 Added 27.83%
1,386,459 $27 Million
Q1 2020

May 14, 2020

SELL
$7.14 - $15.99 $14.4 Million - $32.2 Million
-2,012,402 Reduced 64.98%
1,084,641 $10.7 Million
Q4 2019

Feb 14, 2020

SELL
$5.1 - $11.2 $22.6 Million - $49.6 Million
-4,424,867 Reduced 58.83%
3,097,043 $34.4 Million
Q3 2019

Nov 14, 2019

BUY
$5.38 - $8.99 $11.6 Million - $19.4 Million
2,162,051 Added 40.34%
7,521,910 $42.2 Million
Q2 2019

Aug 15, 2019

BUY
$6.27 - $8.65 $32.9 Million - $45.3 Million
5,241,560 Added 4430.77%
5,359,859 $46.4 Million
Q2 2019

Aug 14, 2019

SELL
$6.27 - $8.65 $30 Million - $41.4 Million
-4,787,487 Reduced 97.59%
118,299 $8.72 Million
Q1 2019

May 14, 2019

BUY
$4.02 - $8.04 $19.2 Million - $38.5 Million
4,786,175 Added 4001.45%
4,905,786 $39.4 Million
Q4 2018

Feb 14, 2019

SELL
$3.44 - $5.76 $556,261 - $931,415
-161,704 Reduced 57.48%
119,611 $490,000
Q3 2018

Nov 14, 2018

SELL
$5.15 - $14.0 $1.26 Million - $3.42 Million
-244,237 Reduced 46.47%
281,315 $1.58 Million
Q2 2018

Aug 14, 2018

BUY
$12.5 - $15.0 $1.69 Million - $2.03 Million
135,562 Added 34.76%
525,552 $6.91 Million
Q1 2018

May 15, 2018

BUY
$8.7 - $16.8 $3.39 Million - $6.55 Million
389,990 New
389,990 $5.54 Million
Q4 2017

Feb 14, 2018

SELL
$7.35 - $12.3 $973,147 - $1.63 Million
-132,401 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$10.0 - $12.7 $1.32 Million - $1.68 Million
132,401
132,401 $1.57 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $5.09B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.